Relationship between liver fat, pancreatic fat, and new-onset type 2 diabetes mellitus in patients with metabolic dysfunction-associated fatty liver disease
- PMID: 40252104
- DOI: 10.1007/s00592-025-02501-7
Relationship between liver fat, pancreatic fat, and new-onset type 2 diabetes mellitus in patients with metabolic dysfunction-associated fatty liver disease
Abstract
Purpose: Type 2 diabetes mellitus (T2DM) is associated with ectopic fat deposition, especially in the liver and pancreas. Therefore, this study aimed to evaluate the relationship between liver fat fraction (LFF), pancreatic fat fraction (PFF), and new-onset T2DM in metabolic dysfunction-associated fatty liver disease (MAFLD) by magnetic resonance imaging (MRI).
Methods: This is a retrospective study of patients with MAFLD who underwent abdominal MRI between 2022 and July 2024. LFF and PFF were measured using an axial multi-echo Dixon-based sequence. All participants underwent routine medical history, anthropometric measurements, and laboratory tests. Multivariable stepwise selection models were constructed to predict PFF and T2DM status based on variables of clinical interest.
Results: This study included 80 MAFLD patients with 40 untreated new-onset T2DM and 40 non-T2DM controls. LFF, PFF, and homeostasis model assessment of insulin resistance (HOMA-IR) index were higher in the T2DM group than in the control group. In the new-onset T2DM group, PFF was linearly positively correlated with LFF (rs = 0.321, P = 0.04) and HOMA-IR (rs = 0.350, P = 0.03). After adjustment for several metabolic variables, PFF remained an independent risk factor for incident T2DM in MAFLD patients (all P < 0.05). The area under the receiver operating characteristic curve for PFF and LFF to predict T2DM was 0.889 and 0.633 (P < 0.001 and P = 0.03), respectively.
Conclusion: In MAFLD patients, PFF, and LFF play a prominent role in new-onset T2DM with high predictive and diagnostic value.
Keywords: Ectopic fat deposition; Liver fat fraction; MRI; Metabolic dysfunction-associated fatty liver disease; Pancreatic fat fraction; Type 2 diabetes mellitus.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict of interest. Ethical Approval: The study was approved by the Ethics Committee of the Affiliated Hospital of Hangzhou Normal University (Hangzhou, China) and conducted by the Declaration of Helsinki. Informed Consent: All participants provided written informed consent.
Similar articles
-
Quantification of ectopic fat storage in the liver and pancreas using six-point Dixon MRI and its association with insulin sensitivity and β-cell function in patients with central obesity.Eur Radiol. 2023 Dec;33(12):9213-9222. doi: 10.1007/s00330-023-09856-x. Epub 2023 Jul 6. Eur Radiol. 2023. PMID: 37410109
-
Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease.Abdom Radiol (NY). 2019 Sep;44(9):3107-3114. doi: 10.1007/s00261-019-02123-y. Abdom Radiol (NY). 2019. PMID: 31312893
-
The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus.Diagnostics (Basel). 2025 Feb 10;15(4):426. doi: 10.3390/diagnostics15040426. Diagnostics (Basel). 2025. PMID: 40002577 Free PMC article.
-
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.Diabetes Metab Syndr Obes. 2023 Oct 25;16:3303-3329. doi: 10.2147/DMSO.S431251. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37905232 Free PMC article. Review.
-
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8421-8443. doi: 10.1007/s00210-024-03204-6. Epub 2024 Jun 11. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38861011 Review.
Cited by
-
Chronic hepatitis B with type 2 diabetes mellitus: Association between glycemic control and liver fibrosis.World J Diabetes. 2025 Jul 15;16(7):107256. doi: 10.4239/wjd.v16.i7.107256. World J Diabetes. 2025. PMID: 40697585 Free PMC article.
-
Effect of short-term (4 weeks) low-calorie diet induced weight loss on beta-cell function in overweight normoglycemic subjects: A quasi-experimental pre-post interventional study.Metabol Open. 2025 Jul 1;27:100378. doi: 10.1016/j.metop.2025.100378. eCollection 2025 Sep. Metabol Open. 2025. PMID: 40689318 Free PMC article.
References
-
- Eslam M, Sanyal AJ, George J (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312 - DOI - PubMed
-
- Le MH, Yeo YH, Li X et al (2022) 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20(12):2809-2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002 - DOI - PubMed
-
- Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14(1):32–42. https://doi.org/10.1038/nrgastro.2016.147 - DOI - PubMed
-
- Chen C, Cohrs CM, Stertmann J, Bozsak R, Speier S (2017) Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab 6(9):943–957. https://doi.org/10.1016/j.molmet.2017.06.019 - DOI - PubMed - PMC
-
- Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053. https://doi.org/10.2337/diacare.27.5.1047 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources